Review: Current clinical applications of chimeric antigen receptor (CAR) modified T cells.
about
In Vivo Murine-Matured Human CD3+ Cells as a Preclinical Model for T Cell-Based Immunotherapies.Incorporation of a hinge domain improves the expansion of chimeric antigen receptor T cells.The basics of CAR T design and challenges in immunotherapy of solid tumors - Ovarian cancer as a model.Chimeric Antigen Receptor (CAR) T Cells: Lessons Learned from Targeting of CD19 in B-Cell Malignancies.Advancing Immune and Cell-Based Therapies Through Imaging.CAR T-cell therapy for pancreatic cancer.Dying to protect: cell death and the control of T-cell homeostasis.Current status and perspectives of chimeric antigen receptor modified T cells for cancer treatment.Complement C3-dependent uptake of targeted liposomes into human macrophages, B cells, dendritic cells, neutrophils, and MDSCsA Review of Immune Therapy in Cancer and a Question: Can Thermal Therapy Increase Tumor Response?Antibody darts on target for acute myelogenous leukemia.Cell and Gene Therapy for HIV Cure.Nonimmune cells equipped with T-cell-receptor-like signaling for cancer cell ablation.CAR T cell therapy for multiple myeloma: where are we now and where are we headed?Anticancer cellular immunotherapies derived from umbilical cord blood.Treatment of Older Patients with Acute Lymphoblastic Leukaemia.Stop and go: hematopoietic cell transplantation in the era of chimeric antigen receptor T cells and checkpoint inhibitors.PSCA and MUC1 in non-small-cell lung cancer as targets of chimeric antigen receptor T cells.Emerging role of immunotherapy in precursor B-cell acute lymphoblastic leukemia.Differences in Expansion Potential of Naive Chimeric Antigen Receptor T Cells from Healthy Donors and Untreated Chronic Lymphocytic Leukemia Patients.Preclinical Assessment of CAR T-Cell Therapy Targeting the Tumor Antigen 5T4 in Ovarian Cancer.Enhanced intracellular delivery via coordinated acoustically driven shear mechanoporation and electrophoretic insertion.The Integration of Biology Into the Treatment of Diffuse Intrinsic Pontine Glioma: A Review of the North American Clinical Trial Perspective.Are ovarian cancer stem cells the target for innovative immunotherapy?The application of CAR-T cell therapy in hematological malignancies: advantages and challenges
P2860
Q33796950-29B5D04E-C3EC-4663-9734-0E3AE71FFDA9Q34553167-447C51CA-A64F-4304-9AB9-1C2EAF0FBF1FQ38748836-F4DEA894-EC26-4F47-B09A-02050E23D312Q39007364-9414C424-57C5-444D-B127-82F52D7432BEQ39167485-4C8FD895-34FA-4838-B910-51150A4B4802Q39202440-0C8DE04D-B77F-40DC-96BC-3BFA9D67ED16Q39277476-564BEA8E-F84A-4C25-AE8A-F8B670B2DCF5Q39280002-1F4C3110-A3EA-444C-9408-537570831C79Q41140076-78F22BA2-6865-4A70-ADC4-7E15A4FF7862Q41928232-0419CD33-F164-46C0-8AC2-68D529559E8BQ42318343-F1E3F958-808C-4B6C-BFBF-5C5DAEF365D1Q47236016-98F698BB-6DDB-4FAF-A90C-38C6B4BBAE57Q47355616-493770A3-4C5F-45E8-9015-89F8E99430FAQ47565827-BC27CE93-9303-4692-8195-7171B2B91520Q47657491-A50FC591-FC33-4303-B4BE-08C1298C7626Q47774455-A9CD9FD5-1E4A-4068-885F-4638C89B7F89Q47855599-5E4BA7EA-A84D-47DD-8026-204EA46A1F5AQ47920923-F066866E-8E71-4A39-90DC-5B7D911AFDD0Q48192887-4892C9EC-8513-4860-A9FD-E4035DBAD24EQ49363296-10530EE6-F9B2-4340-A1BC-CFCDCBBDFD07Q49843670-C45AAE77-EEFB-40D0-A4B7-E54921B4B32FQ52371935-5AC1A66D-D0EF-47FF-8906-04C40261BA47Q55021530-AA50EA64-EEEA-4496-9D25-DB0F3C3CE91EQ55164226-1F846F4E-0AF1-43AE-8F7B-AB35C2E69681Q57177485-AED286CE-474C-40A6-A3DE-E22A42B330E0
P2860
Review: Current clinical applications of chimeric antigen receptor (CAR) modified T cells.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Review: Current clinical appli ...... ceptor (CAR) modified T cells.
@en
type
label
Review: Current clinical appli ...... ceptor (CAR) modified T cells.
@en
prefLabel
Review: Current clinical appli ...... ceptor (CAR) modified T cells.
@en
P2860
P1433
P1476
Review: Current clinical appli ...... ceptor (CAR) modified T cells.
@en
P2093
Renier J Brentjens
P2860
P304
P356
10.1016/J.JCYT.2016.07.003
P50
P577
2016-08-31T00:00:00Z